FDA To Decide On Expanded Use Of Gardasil In Older Women In Mid-June
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck anticipates receiving an FDA decision by mid-June on expanding use of its human papillomavirus Gardasil to women aged 27 through 45
You may also be interested in...
Gardasil For Males Gets FDA OK; Next Up, Cost-Effectiveness Questions
CDC's Advisory Committee on Immunization Practices is slated to consider at an Oct. 21 meeting whether to recommend the vaccine to prevent genital warts in males.
Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest
Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011